A practical reference on lipolysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-14. Anything still debated is marked as such rather than presented as settled.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
== Technology license == The Scripps Research Institute has a portfolio of click-chemistry patents. Licensees include Invitrogen, Allozyne, Aileron, Integrated Diagnostics, and the biotech company baseclick, a BASF spin-off created to sell products made using click chemistry. Moreover, baseclick holds a worldwide exclusive license for the research and diagnostic market for the nucleic acid field. Fluorescent azides and alkynes are also produced by companies such as Cyandye.
Nanoparticles present possible dangers, both medically and environmentally. Most of these are due to the high surface to volume ratio, which can make the particles very reactive or catalytic. They are also thought to aggregate on phospholipid bilayers and pass through cell membranes in organisms, and their interactions with biological systems are relatively unknown. However, it is unlikely the particles would enter the cell nucleus, Golgi complex, endoplasmic reticulum or other internal cellular components due to the particle size and intercellular agglomeration. A recent study looking at the effects of ZnO nanoparticles on human immune cells has found varying levels of susceptibility to cytotoxicity. There are concerns that pharmaceutical companies, seeking regulatory approval for nano-reformulations of existing medicines, are relying on safety data produced during clinical studies of the earlier, pre-reformulation version of the medicine. This could result in regulatory bodies, such as the FDA, missing new side effects that are specific to the nano-reformulation. However considerable research has demonstrated that zinc nanoparticles are not absorbed into the bloodstream in vivo. Concern has also been raised over the health effects of respirable nanoparticles from certain combustion processes. Preclinical investigations have demonstrated that some inhaled or injected noble metal nano-architectures avoid persistence in organisms. As of 2013 the U.S. Environmental Protection Agency was investigating the safety of the following nanoparticles:
Tender pig or boar meat. What is enjoyed by pigs and boars. In the latter meaning, the term has been thought to refer to a mushroom or truffle, or a yam or tuber. The idea that the Buddha's last meal consisted of pork is generally supported by the Theravada tradition; while that it was a vegetarian dish, by the Mahayana tradition. These may reflect the different traditional views on Buddhist vegetarianism and the monastic precepts. In the sutta, the Buddha asks Cunda to serve the rice and cakes to the community of bhikkus, and to only serve the sūkaramaddava to him. Any leftovers should be buried in a pit. Cunda does as he is told. Theravada scholar Buddhaghosa, the author of the earliest extant commentary that refers to the meal, interprets the term sūkara-maddava as the soft and oily flesh of a boar, adding that it was well-cooked under Chunda's instructions. According to later commentator Dhammapāla, this interpretation comes from the older commentary Mahā-atthakathā; Dhammapāla suggests that sūkara-maddava was either a bamboo shoot softened by boars or "mushroom grown in a place softened by boars". Old Chinese texts support Dhammapāla's suggestion, and Pali scholar Thomas William Rhys Davids translates the word as "truffle". Food historian K. T. Achaya notes that the Indian names of multiple plants begin with the word "sūkara" (Sanskrit shukara), so the word likely sūkara-maddava does not refer to pork: other Buddhist texts do not associate the word maddava with meat, and use the term sūkara-māmsa for pork.
Sources: en.wikipedia.org
=== Organic compound peptide-based batteries === StoreDot reported in 2014 to have developed organic-compound peptide-based smartphone batteries capable of being fully charged within 30 seconds. The company said its 30-second-charging organic-compound-based battery would be commercially available for smartphones by 2016. The company announced its 5-minutes-to-full-charge organic batteries will be available for 300-mile-range electric vehicles and aerial drones by 2020. The company acknowledged in 2015 that its claims regarding its organic batteries have not been scientifically peer-reviewed.
=== Aviptadil === In the wake of the COVID-19 pandemic, scientists at Relief conducted initial studies into the efficacy of RLF-100 in treating severe COVID-19 patients. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to RLF-100 for treatment of respiratory distress in COVID-19. In September 2020, Relief partnered with US-Israeli firm NRX Pharmaceuticals (formerly NeuroRx Inc) for the co-development of the drug and the co-ordination of US trials. In April 2021, a reformulated version of aviptadil, known as Zyesami, was included in a National Institutes of Health (NIH) sponsored Phase 3 trial with the aim of testing aviptadil against remdesivir. In May 2021, NRX submitted a request for an Emergency Use Authorization (EUA) to the US FDA for aviptadil's use in patients in intensive care. On 7 October 2021 Relief Therapeutics filed a lawsuit against NRX Pharmaceuticals and its CEO Dr. Jonathan Javitt in the Supreme Court of the State of New York, citing multiple alleged breaches of the collaboration agreement signed by the two companies for the co-development of aviptadil. On 4 November 2021 the FDA declined EUA for the drug, but committed to working with NRX to further develop it. On 29 November 2021, NRX announced that data analysis from the NIH-sponsored Phase 3 trial showed a fourfold increase in survival at 60 days for patients administered with Zyesami (Aviptadil) vs those who received placebo.
The city's automotive industry played a pivotal role in the Italian economic miracle of the 1950s and 1960s, attracting hundreds of thousands of migrants to the city, particularly from the rural southern regions of Italy. The number of migrants was so high that Turin was said to be "the third southern Italian city after Naples and Palermo". The population soon reached 1 million in 1960 and peaked at almost 1.2 million in 1971. The exceptional growth gains of the city gained it the nickname of Capitale dell'automobile (Automobile Capital), being often compared with Detroit, the major centre of the U.S. automobile industry (these cities were 'twinned' as sister cities in 1998). In the 1970s and 1980s, the oil and automotive industry crisis severely hit the city, and its population began to sharply decline as jobs were lost. In 30 years, the population decreased by more than one-fourth of the 1971 total. The long population decline of the city has begun to reverse itself only in recent years; the population grew from 865,000 to slightly over 900,000 by the end of the 20th century. In 2006, Turin hosted the Winter Olympic Games.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.